Roche's Actemra wins new RA indication; Allergan fails to save Sanctura XR patent;

@FiercePharma: Profile of one man who's shaking up India's patent-protected drugmakers: Cipla founder YK Hamied. More | Follow @FiercePharma

> Roche's ($RHHBY) arthritis drug Actemra won FDA approval for a new indication in adults with moderate to severe disease who've failed on disease-modifying antirheumatic drugs such as methotrexate. Report

> Allergan ($AGN) failed to convince the Supreme Court to weigh its patent on the bladder drug Sanctura XR, which was invalidated by a U.S. appeals court in June, clearing the way for Watson Pharmaceuticals ($WPI) to launch its generic version. News | Report

> The Irish government and the pharma industry came to a deal on drug prices, which includes a big, two-step cut in generics prices and a one-time cut in branded drug prices. Report

> Onyx Pharmaceuticals ($ONXX) wrapped up enrollment for a Phase 3 trial of Kyprolis, which will test the drug as monotherapy in multiple myeloma patients whose treatment with three other therapies has failed. Release

> Teva Pharmaceuticals Industries ($TEVA) opened its new, $110 million in Hungary, which will supply 70 countries in Europe, North America and Asian. Report

> Shanghai Fosun Pharmaceutical plans to launch its Hong Kong stock offering Tuesday, aiming to raise up to $600 million. Report

Biotech News

 @FierceBiotech: How should India regulate its clinical trial industry? More | Follow @FierceBiotech

 @JohnCFierce: Zounds! Sloan-Kettering won't use Zaltrap (Sanofi/Regeneron) based on its cost and efficacy. Influential. More | Follow @JohnCFierce

 @RyanMFierce: New website crowdsources cancer therapies (some ideas more useful than others). More | Follow @RyanMFierce

> Aegerion shares surge on FDA review of rare cholesterol disease drug. Report

> Merck hooks late-stage infectious-disease portfolio with $571M deal. Article

> AstraZeneca turns to Beijing CRO as it scrambles to repair damaged pipeline. News

Medical Device News

 @FierceMedDev: Heart stent surgeries in China are now second only to the U.S., but more than half may be unnecessary. More | Follow @FierceMedDev

 @MarkHFierce: BSX CEO explains its repositioning is an attempt, in part, to respond to a rapidly changing healthcare industry. More | Follow @MarkHFierce

 @DamianFierce: Will GSK's new transparency pledge be a boon for CROs and drug developers? More | Follow @DamianFierce

> Medtronic, St. Jude Medical pursue diversity as MN mulls same-sex marriage ban. Item

> BD, Lab21 team up for cancer diagnostics. Story

Biotech IT News

> Australia goes online for clinical trials awareness. Report

> Fight against 'unwarranted' drug patents goes online. More

> GSK to open clinical data vaults to scientists via website. Story

> Pharma group taps software to track adverse events in mobile apps. Article

CRO News

> How should India regulate its clinical trial industry? Item

> AstraZeneca taps China's Pharmaron to speed R&D. Report

> GSK's transparency pledge could be a boon to drug researchers. News

> Recipharm teams with Astimex on CDMO deal. Story

> Novasep pours $39M into new API plant. Article

And Finally... Children with ADHD said that their drug treatment helps them control their behavior, a study found. More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.